Nedosiran sodium
Based on 1 publication(s) in Google Scholar
Nedosiran (DCR-PHXC) sodium is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran sodium represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran sodium is a GalNAc-dsRNA conjugate.
For research use only. We do not sell to patients.
- Purity: 92.35%
- CAS No.: 2247026-22-6
- Formula: C662H865F19N231O413P57S6.xNa
- Molecular Weight:20985 (free acid)
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Nedosiran sodium
More
Biological Activity
Nedosiran sodium is a synthetic, double-stranded RNA oligonucleotide (i.e., small interfering RNA [siRNA]) designed to target the mRNA encoding LDHA[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Nedosiran sodium specially inhibits hepatic expression of lactate dehydrogenase (LDHA)[3].
Nedosiran sodium is a double-strand siRNA molecule that is conjugated with GalNAc, which takes advantage of the aforementioned unique asialoglycoprotein receptor (ASGPR) delivery system in the liver. Nedosiran sodium is administered by monthly subcutaneous injection. Nedosiran sodium decreases plasma oxalate in animal models[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2247026-22-6
-
Appearance Solid
-
Molecular Weight 20985 (free acid)
-
Formula C662H865F19N231O413P57S6.xNa
-
Color White to off-white
-
SMILES
[Nedosiran (sodium)]
-
Synonyms
DCR-PHXC sodium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Drug Metab Dispos
Comparative evaluation of ultrafiltration and EMSA formats for siRNA plasma protein binding: Methodological determinants and artifacts. [Abstract]2026 Jun;54(6):100301. PMID: 42214258
Solvent & Solubility
H2O : 100 mg/mL (Need ultrasonic)
Purity & Documentation
-
Data Sheet (269 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2242 KB)
References
[1]. Kevin Shee, et al. Nedosiran Dramatically Reduces Serum Oxalate in Dialysis-Dependent Primary Hyperoxaluria 1: A Compassionate Use Case Report. Urology.2021 Oct;156:e147-e149. [Content Brief]
[2]. Gema Ariceta, et al. Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria. Kidney Int Rep. 2021 Feb 3;6(4):1088-1098. [Content Brief]
[3]. Thomas A Forbes, et al. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria. Br J Clin Pharmacol. 2021 May 22. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)